Join to view full profile
530 East 74thMSKCC-KochNew York, NY 10021
Phone+1 646-608-3703
Fax+1 929-321-8156
Dr. Joffe is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a lymphoma specialist, hemato-oncologist and biomedical informatician. I specialize in treating all types of lymphoma, and have a special research focus on follicular, small lymphocytic, marginal zone, and mantle cell lymphomas. I also have extensive experience in treating more aggressive types, such as Diffuse-Large B-cell, Hodgkin’s, and Burkitt’s lymphomas. I am grateful and honored to be part of MSK’s lymphoma team, delivering the most cutting-edge care to our patients.
Education & Training
Tel Aviv University SacklerClass of 2007
Certifications & Licensure
FL State Medical License 2021 - Present
MI State Medical License 2026 - 2029
MA State Medical License 2026 - 2027
NY State Medical License 2018 - 2027
TN State Medical License 2026 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
Clinical Trials
- Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2018 Oct 24
- CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) Start of enrollment: 2017 Dec 28
- A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2019 Apr 03
Publications & Presentations
PubMed
- Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma.Magdalena Corona, Aaron Gillmor, Kimon V Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva
Blood Cancer Discovery. 2026-11-03 - A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies.Mark Hertzberg, Chan Y Cheah, Stephen Opat, Matko Kalac, Pau Abrisqueta
Blood Cancer Discovery. 2026-09-30 - 1 citationsMutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.Erel Joffe, Manik Uppal, Serena Zheng, Kurt S Bantilan, Connie Batlevi
Haematologica. 2026-08-01
Abstracts/Posters
- Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin LymphomaErel Joffe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)Erel Joffe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...Erel Joffe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Member
- Member
- European Hematology AssociationMember
Other Languages
- Hebrew
Industry Relationships
- Advisory Board, Epizyme2020 - Present
- Advisory board, AstraZeneca2020 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
